Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Icotrokinra appears to be an effective treatment for adolescents with moderate to severe plaque psoriasis, according to a subgroup analysis of the ICONIC-LEAD study.

New data presented at the 2025 World Congress of Pediatric Dermatology annual meeting highlights the efficacy and safety of ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that ebdarokimab, an investigational monoclonal antibody developed by the company, has received marketing approval from the ...

In the Phase III ICONIC-LEAD trial, 75% of adolescents with moderate-to-severe plaque psoriasis treated with icotrokinra ...

Johnson & Johnson (J&J) has reported data from the Phase III ICONIC-LEAD trial’s subgroup analysis evaluating icotrokinra in ...

New results from a subgroup analysis of the ICONIC-LEAD study showed icotrokinra was effective and safe for the treatment of moderate to severe plaque psoriasis in adolescents, according to a press ...

In this video, Raj Chovatiya, MD, PhD, discusses findings from the phase 2 STRIDE trial presented at this year’s American ...

Icotrokinra is efficacious and safe for treating moderate to severe plaque psoriasis among adolescents and adults when compared with placebo.

Results from a subgroup of the ICONIC-LEAD study show 75% of adolescents with plaque psoriasis achieved completely clear skin ...